(1) Background: In patients hospitalized with COVID-19 pneumonia, especially moderate
and severe forms, a cytokine storm may occur, characterized by the worsening of symptoms …

Objective: Cytokine storm is considered as the immune hyperinflammatory process which
may deteriorate the course of COVID-19. Interleukin (IL-6) inhibitors can be used in severe …

For some patients with SARS-CoV-2, the worst clinical damage is not caused by the virus
itself, but by an overactive inflammatory state. In fact, in some people the immune system …

To recognize the period of exaggerated cytokine response in patients with coronavirus
disease 2019 (COVID‐19) pneumonia, and to describe the clinical outcomes of using …

Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to
COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the …

Objectives Patients who develop cytokine storm while they have coronavirus disease 2019
(COVID-19) experience more severe symptoms. This article aims to evaluate the effect of …

We have read with special interest Cardona-Pascual et al.'s 1 study on the effect of
tocilizumab versus standard of care in patients hospitalized with moderate-severe …

Coronavirus disease 2019 (COVID-19) is characterized by immune activation in response to
viral spread, in severe cases leading to the development of cytokine storm syndrome (CSS) …

Objective Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop
a life-threatening pneumonia that often occurs in the setting of increased inflammation or …

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent
of coronavirus disease 2019 (COVID-19), produces protean manifestations and causes …